This invention relates to an anionic-cationic-nonionic surfactant as substantially represented by the formula (I), production and use thereof in tertiary oil recovery. The anionic-cationic-nonionic surfactant of this invention exhibits significantly improved interfacial activity and stability as compared with the prior art. With the present anionic-cationic-nonionic surfactant, a flooding fluid composition for tertiary oil recovery with improved oil displacement efficiency and oil washing capability as compared with the prior art could be produced. ##STR00001## In the formula (I), each group is as defined in the specification.

This invention relates to an anionic-cationic-nonionic surfactant as substantially represented by the formula (I), production and use thereof in tertiary oil recovery. The anionic-cationic-nonionic surfactant of this invention exhibits significantly improved interfacial activity and stability as compared with the prior art. With the present anionic-cationic-nonionic surfactant, a flooding fluid composition for tertiary oil recovery with improved oil displacement efficiency and oil washing capability as compared with the prior art could be produced. ##STR00001## In the formula (I), each group is as defined in the specification.

Provided is a quaternary ammonium surfmer, that may have the following general formula (I): N.sup.+—R.sup.1R.sup.2R.sup.3R.sup.4 (X.sup.−), where: R.sup.1 and R.sup.2 may independently be H or a C.sub.1-C.sub.3 alkyl, R.sup.3 may be a C.sub.19+ amidoalkyl group, R.sup.4 may be a C.sub.3-C.sub.6 alkyl having a terminal olefin double bond group, and X may be a halogen. Further provided is a method for synthesizing the quaternary ammonium surfmer and a method for recovering hydrocarbons from a subterranean formation that may include injecting a treatment fluid comprising the quaternary ammonium surfmer into the subterranean formation.

The disclosure provides ionizable amine lipids and salts thereof (e.g., pharmaceutically acceptable salts thereof) useful for the delivery of biologically active agents, for example delivering biologically active agents to cells to prepare engineered cells. The ionizable amine lipids disclosed herein are useful as ionizable lipids in the formulation of lipid nanoparticle-based compositions.

The disclosure provides ionizable amine lipids and salts thereof (e.g., pharmaceutically acceptable salts thereof) useful for the delivery of biologically active agents, for example delivering biologically active agents to cells to prepare engineered cells. The ionizable amine lipids disclosed herein are useful as ionizable lipids in the formulation of lipid nanoparticle-based compositions.

The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

Compounds and methods for use in detecting gabapentin in a sample suspected of containing gabapentin are disclosed. Gabapentin derivatives are used to produce gabapentin conjugates. A gabapentin-immunogenic carrier conjugate may be used as an immunogen for the preparation of an anti-gabapentin antibody. A gabapentin-detectable label may be used in a signal producing system in gabapentin assays.

Compounds and methods for use in detecting gabapentin in a sample suspected of containing gabapentin are disclosed. Gabapentin derivatives are used to produce gabapentin conjugates. A gabapentin-immunogenic carrier conjugate may be used as an immunogen for the preparation of an anti-gabapentin antibody. A gabapentin-detectable label may be used in a signal producing system in gabapentin assays.

The instant invention concerns a gas hydrate inhibitor comprising an N alkyl N′ (N″,N″-dialkylammoniumalkyl)dicarboxylic acid diamide salt represented by the formula (I) ##STR00001##
wherein R is an alkyl or alkenyl group having from 8 to 22 carbon atoms, R.sup.1 is hydrogen, a C.sub.1- to C.sub.22 alkyl group or a C.sub.3- to C.sub.22 alkenyl group, R.sup.2 and R.sup.3 are each independently an alkyl group containing 1 to 10 carbon atoms or together form an optionally substituted ring having 5 to 10 ring atoms, wherein the ring may carry up to 3 substituents, R4 is hydrogen, A is an optionally substituted hydrocarbyl group containing from 1 to 18 carbon atoms, B is an alkylene group having from 2 to 6 carbon atoms, Y is NR.sup.5, R.sup.5 is hydrogen, a C.sub.1- to C.sub.22 alkyl group or a C.sub.3- to C.sub.22 alkenyl group, and M− is an anion,
a process for producing a compound according to formula (I), the use of an N alkyl N′—(N″,N″-dialkylammoniumalkyl)dicarboxylic acid diamide salt of the formula (I) as an anti-agglomerant for gas hydrates, and a method for inhibiting the agglomeration of gas hydrates which comprises the addition of an N alkyl N′ (N″,N″dialkylammmoniumalkyl)dicarboxylic acid diamide salt of the formula (I) to a fluid containing gas and water.